Tykerb Effective In Herceptin Failures; CNS Relapse Rate, CV Safety Touted

GlaxoSmithKline's Tykerb (lapatinib) should replace Genentech's Herceptin (trastuzumab) as the standard of care for trastuzumab-refractory breast cancer patients, GSK Senior VP-Oncology Medicine Development Center Paolo Paoletti said June 3